Back to top
more

ACADIA Pharmaceuticals (ACAD)

(Real Time Quote from BATS)

$30.50 USD

30.50
476,719

+0.85 (2.87%)

Updated Aug 25, 2026 12:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (159 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Why Is CRISPR Therapeutics (CRSP) Up 3.3% Since Last Earnings Report?

by Zacks Equity Research

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why Is Acadia (ACAD) Up 22.6% Since Last Earnings Report?

by Zacks Equity Research

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y

by Zacks Equity Research

NKTR posts a narrower Q3 loss and a revenue beat, while its rezpeg program advances with key phase IIb milestones.

Zacks Equity Research

Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble

by Zacks Equity Research

Despite a narrower Q3 loss, NTLA stock plunges after pulling nex-z milestone guidance amid FDA scrutiny in amyloidosis patients.

Zacks Equity Research

ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth

by Zacks Equity Research

Acadia's third-quarter earnings and revenues top forecasts as Nuplazid and Daybue sales power double-digit annual growth.

Zacks Equity Research

Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y

by Zacks Equity Research

CPRX Q3 earnings and revenues beat estimates, driven by strong Firdapse and Agamree sales, while raising the full-year 2025 total revenue guidance.

Zacks Equity Research

RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y

by Zacks Equity Research

Recursion Pharmaceuticals narrows its Q3 loss but posts lower-than-expected revenues due to reduced collaboration revenues from its partners.